CG Oncology

CGON on Nasdaq. Biological products, (no diagnostic substances). Market value $6.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-3.2%low

For every $100 of what the whole company costs, it produced $-3.18 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$63.64 a share, 78% above its 1-year low

Over the past year the price has ranged from $35.80 to $80.97.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
-0.2
2024202512 monthsto Jun '26
Revenue
$1m$4m
Operating margin
-10067.3%-4722.1%
Debt to equity
0.000.00
Shares outstanding
0.08bn0.09bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.00× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 10% more shares since 2024

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $79 million, compared with a loss of $41 million a year ago.
  • It loses 4056 cents on each $1 of sales, compared with 28546 cents a year earlier.
  • Over the past 12 months it spent $179 million more cash than it brought in, compared with $94 million a year earlier.
  • 16% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$43,000
December 2024$456,000
March 2025$52,000
June 2025$0
September 2025$2m
December 2025$2m
March 2026$1m
June 2026$1m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$20m
December 2024-$32m
March 2025-$34m
June 2025-$41m
September 2025-$44m
December 2025-$41m
March 2026-$60m
June 2026-$79m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
27 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

None of the long-term investors we follow own it. 227 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

11 investors own more than 5%.

  • RTW Investments, LP
    Passive investor
    at least 9.7%+1.4 pts
    (filed with 1 related holder)
    Since 30 June 2026
  • Xiangmin Cui
    Passive investor
    at least 8.4%
    (filed with 4 related holders)
    Since 31 December 2024
  • Since 31 March 2026
  • BlackRock, Inc.
    Passive investor
    6.8%
    Since 30 June 2026
  • at least 6.0%−1.2 pts
    (filed with 3 related holders)
    Since 30 June 2026
  • Patrick G. Enright
    Passive investor
    at least 6.0%
    (filed with 5 related holders)
    Since 11 September 2025
    What they said

    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other…

    Read the filing
  • SONG, Hong Fang
    Passive investor
    at least 5.5%
    (filed with 9 related holders)
    Since 31 December 2024
  • FMR LLC
    Passive investor
    at least 5.1%
    (filed with 1 related holder)
    Since 30 June 2025
  • James B. Tananbaum
    Passive investor
    at least 4.9%
    (filed with 6 related holders)
    Since 30 June 2026
  • TCG Crossover GP I, LLC
    Passive investor
    at least 4.8%
    (filed with 2 related holders)
    Since 31 March 2025
  • Brian Liu
    Passive investor
    at least 2.0%0.0 pts
    (filed with 3 related holders)
    Since 6 October 2025
    What they said

    Item 4 of the Schedule 13D is amended to add the following: The Reporting Persons effected an internal restructuring into a master-feeder structure, pursuant to which Seven Fleet Partners LP contributed, for no consideration, all of the 1,515,151 Shares it then held to Seven…

    Read the filing
  • Seven Fleet Partners LP
    Passive investor
    Sold down below 5%
    Since 11 September 2025
    What they said

    The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the…

    Read the filing
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $25m of shares on the open market. 2 sold $5m, $5m of it under preset trading plans.

  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    15 September 2026
    Shares
    1,000
    Price
    $72.98
    Value
    $72,980
  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    14 August 2026
    Shares
    1,000
    Price
    $74.54
    Value
    $74,540
  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    15 July 2026
    Shares
    1,000
    Price
    $71.17
    Value
    $71,170
  • Mulay James
    Director
    Sold
    under a preset trading plan
    Date
    10 July 2026
    Shares
    24,165
    Price
    $75.16
    Value
    $2m
  • Liu Brian Guan-Chyun
    Director
    Bought
    under a preset trading plan
    Date
    25 June 2026
    Shares
    371,085
    Price
    $66.87
    Value
    $25m
  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    24 June 2026
    Shares
    5,000
    Price
    $70.00
    Value
    $350,000
  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    22 June 2026
    Shares
    5,000
    Price
    $65.00
    Value
    $325,000
  • Mulay James
    Director
    Sold
    under a preset trading plan
    Date
    15 June 2026
    Shares
    1,964
    Price
    $60.12
    Value
    $118,076
  • POST LEONARD E
    Director
    Sold
    under a preset trading plan
    Date
    4 June 2026
    Shares
    1,000
    Price
    $54.50
    Value
    $54,500
  • Mulay James
    Director
    Sold
    under a preset trading plan
    Date
    17 April 2026
    Shares
    15,600
    Price
    $73.01
    Value
    $1m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 27 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.